SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Dr. Leigh H. Simmons: A 93-year-old woman was evaluated by her primary care physician because of dyspnea. The patient had been in her usual state of health, which included being independent with ...

Dear Dr. Roach: I am a 64-year-old man who has been having periodic shortness of breath for the past six months or so. This happens mostly upon exertion but sometimes occurs when I stand up. I do have ...

Researchers have developed cutting-edge MRI technology to diagnose a common heart problem more quickly and accurately than ever before. Aortic stenosis is a progressive and potentially fatal condition ...

Something as small as the opening at the end of your penis can cause trouble. Some people call it your "pee hole." Meatal stenosis means this opening is too narrow. And passing urine (pee) can cause ...

Having any sleep disorder was independently linked to a higher likelihood for developing aortic stenosis, although dyslipidemia appeared to be an important mediator of the risk Data from the TriNetX ...

Ataciguat, a novel anthranilic acid derivative, may safely slow progression of valve calcification and potentially delay the need for intervention in patients with fibrocalcific aortic valve stenosis, ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...

Sodium-glucose cotransporter 2 (SGLT2) inhibition seems to reduce the progression of nonsevere aortic stenosis over 5 years, with a larger treatment effect seen in those who take the drugs the longest ...

AS plus ATTR-CA was associated with worse clinical outcomes than AS alone. Challenges of diagnosis stand in the way of timely treatment of ATTR-CA. Certain features associated with ATTR-CA and AS may ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...